Read as PDF
Lund, Sweden, 9th of May 2017 – The
Board of Xintela AB (publ) announces that Keld Søndergaard has been nominated for
election as a new member of the Board at the annual general meeting on the 18th
of May 2017. Also proposed for re-election are Greg Batcheller, Karin
Wingstrand, Sven Kili and Claes Post. The proposal is supported by shareholders
who represent a majority of the company´s outstanding shares and votes. It is
also announced that board member Anders Ermén has decided not to stand for re-election.
Keld Søndergaard has more than 30 years of experience from
leadership positions in companies within the industrial sector, asset
management and biotech. He is currently the CFO of Dermtreat ApS, a company
developing an innovative drug delivery system.
He has also co-founded and developed Accunia to become a successful
asset management company with more than DKK 5,7 billion in assets under
management.
“Electing Keld Søndergaard
as a member of the Board would broaden Xintela´s expertise within developing
and financing companies during periods of strong growth. His knowledge,
experience and network of contacts are of great value to the company as our
ambition is to maintain a high pace in our ongoing development projects within
regenerative medicine and cancer while aiming to initiate clinical studies”,
says Xintela's Chairman of the Board Gregory Batcheller.
The Board would also like to thank Anders Ermén for
his active involvement as a member of the Board since 2013 and wishes him every
success with his ongoing and future assignments.
Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: 070-329 18 71
Email: evy@xintela.se
Medicon Village
223 81 Lund
www.xintela.se
For investor relations and media questions, please
contact:
Mårten Svanberg, Laika Consulting
Tel: 070-362 70 05
Email: marten.svanberg@laika.se
www.laika.se
About
Xintela
Xintela AB (publ) is a Swedish biomedical
company active in the fields of regenerative medicine and cancer, with a focus
on cartilage damage and brain tumours. The key to Xintela's business is the
Company's patented marker technology, XINMARK™. Xintela's markers are specific
proteins which sit as "recognition flags" on certain cell
surfaces. The markers make it possible
to identify and quality assure cartilage cells and stem cells and also to
select a certain type of stem cells which can develop into cartilage cells. Through
this technology, Xintela can, in a unique way, quality assure stem cells for
the repair of damaged cartilage. The XINMARK™-technology makes it also possible
to direct antibody treatment to cells in glioblastoma brain tumours with the
goal to slow down tumour growth. Xintela is listed on Nasdaq First North
Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First
North is Erik Penser Bank AB, +46 8-463 80 00.
This information is information that Xintela AB (publ) is obliged to
make public pursuant to the EU Market Abuse Regulation. This information was
submitted for publication through the agency of the contact persons set out
above on 9 May 2017, at 08:45 CET.
Below you will find the collected information on Xintela’s press releases, newsletters, diary events, films, media coverage and analyses.
Chairman Gregory Batcheller visited BioStock’s studio to tell us more about the company’s journey and business development.
CEO Evy Lundgren-Åkerlund presents the company at BioStock Investor Meeting on March 16, 2023.
CEO Evy Lundgren-Åkerlund presents the company at BioStock Life Science Fall Summit 2022 on November 30.
CEO Evy Lundgren-Åkerlund presents the company at Aktiespararnas Småbolagsdagarna 2022 (in Swedish).
Targinta's CEO Per Norlén presents the company at Aktiespararnas Småbolagsdagarna 2022 (in Swedish).
CEO Evy Lundgren-Åkerlund presents the company at BioStock Life Science Spring Summit 2022.
Watch the video interview with CEO Evy Lundgren-Åkerlund (in Swedish).
BioStock interview with Xintela's CMO and board member Sven Kili.
BioStock was given the opportunity to interview Sven Kili in connection with his visit to Sweden for board and strategy work in Xintela.
Dr. Marcus Keep comments on Xintelas glioblastoma project.
Xintelas Chairman of the board and strategic advisor Greg Batcheller, tells us more about Xintelas potential and prospects.
Dr. Lisa Fortier at Cornell University, New York is interviewed by BioStock about Xintelas positive results in horse study.
In the following video interview, Karin explains her role at Xintela and what she considers to be Xintela’s primary strengths.
See the interview with Claes Post, member of the board in Xintela. The interview is in swedish with english subtitles.
See the interview with Sven Kili, member of the board in Xintela. The interview is in English (introduction is in Swedish).
See an interview with Xintela's CEO Evy Lundgren-Åkerlund, after the listing ceremony at Nasdaq First North.